Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 RMI ... chronic orthopedic conditions such as meniscal tears, ACL ... and joint pain due to degenerative conditions like ... orthopedic surgeries to promote better post-surgical outcomes. , ... nearly pain-free bone marrow harvesting with two complimentary ...
(Date:3/4/2015)... USDM Life Sciences , a ... industry, hired David Blewitt as Vice President ... Services and Solutions at USDM Life Sciences , which ... maintaining compliance with government regulations worldwide. , For ... life sciences regulatory and IS compliance professional with extensive ...
(Date:3/4/2015)... 04, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... Optimize the Management of Pain”. , The continuing ... for the next year. The focus of the ... recognize inadequate pain treatments, integrate appropriate pain management ...
(Date:3/4/2015)... Launched by the Assistance ... in December 2011, ,SARAH, - the French national ... sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled more ... SARAH, a large French study of patients with ... has completed patient enrolment, exceeding its 400-patient target, according ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... by Albert Einstein College of Medicine researchers published in ... major scientific ... of,"hibernation on demand" in mice by administering an experimental drug from,Ikaria ... a study designed to reduce damage from heart attacks. The,study was ...
... a nationwide,service based in Winston-Salem that lets ... that it has formed a strategic partnership,with ... Web sites featuring innovative patient education services. ... between DrScore and Vivacare, the,companies will co-market ...
... Sept. 25 SeqWright, Inc., an international,leader in ... an,agreement with Applied Biosystems (ABI) to purchase ABI,s ... will enable,SeqWright to offer commercial access to the ... standing relationship between,SeqWright and ABI that grows stronger ...
Cached Biology Technology:New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces 2New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces 3DrScore.com Partners With Vivacare For Patient Education And Feedback 2SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System 2
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:2/5/2015)... Jan. 30, 2015  It is gratifying to see ... potential for genomic science as a means to better ... and treatment.  I was honored to participate in today,s ... medicine program. Since the 1980s my ... genomics—from the first sequenced genome of a free living ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... are attempting to predict the future impacts of climate ... and ocean circulation. In a November special issue ... scientists report that if current patterns of change in ... ocean circulation could occur on a global scale, with ...
... The answer to successful revegetation of native flora is ... remnant local native vegetation to provide seed. "A ... best source of seed for revegetation projects," says Dr ... "It has been presumed that local seed ...
... produce a variety of hydrocarbon components of diesel fuel. ... (NRRL 50073), lives quietly within ulmo trees in ... State University has found that the fungus produces many ... can be varied by changing the growing medium and ...
Cached Biology News:Ecologists use oceanographic data to predict future climate change 2Ecologists use oceanographic data to predict future climate change 3Obscure fungus produces diesel fuel components 2
...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
... Components: MBP Coated ... Assay Dilution Buffer, 5X, #20 Magnesium/ATP Cocktail, ... Buffer, 10X LumiGLO™ Chemiluminescen LumiGLO™ Chemiluminescen ... enzyme assay Quality Assurance: ...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
Biology Products: